Biofrontera Statistics
Total Valuation
Biofrontera has a market cap or net worth of $5.55 million. The enterprise value is $5.37 million.
| Market Cap | 5.55M |
| Enterprise Value | 5.37M |
Important Dates
The last earnings date was Wednesday, May 15, 2024, after market close.
| Earnings Date | May 15, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Biofrontera has 5.09 million shares outstanding. The number of shares has increased by 171.44% in one year.
| Shares Outstanding | 5.09M |
| Shares Change (YoY) | +171.44% |
| Shares Change (QoQ) | +134.34% |
| Owned by Insiders (%) | 28.19% |
| Owned by Institutions (%) | 40.60% |
| Float | 2.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.17 |
| Forward PS | 0.13 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.16 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.44
| Current Ratio | 1.44 |
| Quick Ratio | 0.54 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.54 |
Financial Efficiency
Return on equity (ROE) is -1,217.20%.
| Return on Equity (ROE) | -1,217.20% |
| Return on Assets (ROA) | -74.80% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | $400,627 |
| Profits Per Employee | -$278,193 |
| Employee Count | 83 |
| Asset Turnover | 1.08 |
| Inventory Turnover | 2.50 |
Taxes
In the past 12 months, Biofrontera has paid $10,000 in taxes.
| Income Tax | 10,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -87.56% in the last 52 weeks. The beta is 0.66, so Biofrontera's price volatility has been lower than the market average.
| Beta (1Y) | 0.66 |
| 52-Week Price Change | -87.56% |
| 50-Day Moving Average | 1.57 |
| 200-Day Moving Average | 3.98 |
| Relative Strength Index (RSI) | 35.83 |
| Average Volume (30 Days) | 614,003 |
Short Selling Information
The latest short interest is 23,811, so 0.47% of the outstanding shares have been sold short.
| Short Interest | 23,811 |
| Short Previous Month | 43,979 |
| Short % of Shares Out | 0.47% |
| Short % of Float | 0.91% |
| Short Ratio (days to cover) | 0.20 |
Income Statement
In the last 12 months, Biofrontera had revenue of $33.25 million and -$23.09 million in losses. Loss per share was -$10.20.
| Revenue | 33.25M |
| Gross Profit | 16.29M |
| Operating Income | -22.35M |
| Pretax Income | -23.08M |
| Net Income | -23.09M |
| EBITDA | -20.14M |
| EBIT | -21.24M |
| Loss Per Share | -$10.20 |
Balance Sheet
The company has $3.84 million in cash and $3.67 million in debt, giving a net cash position of $174,000 or $0.03 per share.
| Cash & Cash Equivalents | 3.84M |
| Total Debt | 3.67M |
| Net Cash | 174,000 |
| Net Cash Per Share | $0.03 |
| Equity / Book Value | -5.42M |
| Book Value Per Share | -1.06 |
| Working Capital | 6.12M |
Cash Flow
In the last 12 months, operating cash flow was -$24.53 million and capital expenditures -$48,000, giving a free cash flow of -$24.58 million.
| Operating Cash Flow | -24.53M |
| Capital Expenditures | -48,000 |
| Free Cash Flow | -24.58M |
| FCF Per Share | -$6.78 |
Margins
Gross margin is 48.99%, with operating and profit margins of -67.22% and -69.44%.
| Gross Margin | 48.99% |
| Operating Margin | -67.22% |
| Pretax Margin | -69.41% |
| Profit Margin | -69.44% |
| EBITDA Margin | -60.55% |
| EBIT Margin | -63.88% |
| FCF Margin | -73.92% |
Dividends & Yields
Biofrontera does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -171.44% |
| Shareholder Yield | -171.44% |
| Earnings Yield | -416.23% |
| FCF Yield | -443.07% |
Analyst Forecast
The average price target for Biofrontera is $18.00, which is 1,582.24% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $18.00 |
| Price Target Difference | 1,582.24% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 25.98% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on July 5, 2023. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jul 5, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
Biofrontera has an Altman Z-Score of -7.35 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.35 |
| Piotroski F-Score | 3 |